Removing inactive NRTIs in a salvage regimen is safe, maintains virological suppression and reduces treatment costs: results from the VERITAS study (TMC114HIV4054)

References

• European AIDS Clinical Society. EACS Guidelines. http://eacsociety.org/Portals/0/140601_EACS%20EN7.02.pdf. Accessed July 2014.
   Google Scholar
• Günthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, et al. Antiretroviral treatment of adult HIV infection: recommendations of the international antiviral society – USA panel. JAMA. 2014;312(4):410–425.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed July 2014.
   Google Scholar
• Campbell TB, Shulman NS, Johnson SC, Zolopa AR, Young RK, Bushman L, et al. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin Infect Dis. 2005;41(2):236–242.
   PubMed Web of Science ®Google Scholar
• Castagna A, Danise A, Menzo S, Galli L, Gianotti N, Carini E, et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS. 2006;20(6):795–803.
   PubMed Web of Science ®Google Scholar
• Katlama C, Clotet B, Plettenberg A, Jost J, Arasteh K, Bernasconi E, et al. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study Team. AIDS. 2000;14(7):781–789.
   PubMed Web of Science ®Google Scholar
• Squires K, Pozniak AL, Pierone G Jr, Steinhart CR, Berger D, Bellos NC, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med. 2003;139(5 Pt 1):313–320.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Hoh R, Neilands TB, Liegler T, Aweeka F, Petropoulos CJ, et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis. 2005;192(9):1537–1544.
   PubMed Web of Science ®Google Scholar
• Trottier B, Thomas R, Nguyen VK, Vezina S, Lavoie S, Longpré D, et al. Should inactive nucleotide/side reverse transcriptase inhibitors (NRTIs) still be used in salvage regimens, with new classes/generations of antiretrovirals in three-class-experienced, multi-drug resistant patients? [Abstract TUPDB205]. Poster presented at: 5th International AIDS Conference on HIV Pathogenesis, Treatment and Prevention; July 19–July 22, 2009; Cape Town, South Africa.
   Google Scholar
• Achhra AC, Boyd MA. Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature. AIDS Res Ther. 2013;10(1):33.
   PubMed Web of Science ®Google Scholar
• Tashima K, Smeaton L, Andrade A, Eron J, Fichtenbaum C, Gandhi R, et al. Omitting NRTIs from ARV regimens is not inferior to adding NRTI in treatment-experienced HIV+ subjects failing a protease inhibitor regimen: the ACTG OPTIONS study [Abstract 153LB]. Paper presented at: 20th Conference on Retroviruses and Opportunistic Infections; March 3–6, 2013; Atlanta.
   Google Scholar
• Imaz A, Llibre JM, Mora M, Mateo G, Camacho A, Blanco JR, et al. Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals. J Antimicrob Chemother. 2011;66(2):358–362.
   PubMed Web of Science ®Google Scholar
• Stanford University HIV Drug Resistance Database. HIV db Program Genotypic Resistance Interpretation Algorithm. http://hivdb.stanford.edu/pages/algs/HIVdb.html.
   Google Scholar
• Trottier B, Longpré D, Dion H, Vezina S, Lavoie S, Galanakis C, et al. Removing inactive NRTIs in a salvage regimen is safe, maintains virological suppression and reduces treatment costs: 96 weeks post VERITAS study. J Int AIDS Soc. 2014;17(4 Suppl 3):19815.
   PubMed Web of Science ®Google Scholar
• Florence E, De Wit S, Castagna A, Ribera E, Hill A, Vanaken H, et al. HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme. Int J STD AIDS. 2010;21(3):224–225.
   PubMed Web of Science ®Google Scholar
• Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370(9581):39–48.
   PubMed Web of Science ®Google Scholar
• Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370(9581):29–38.
   PubMed Web of Science ®Google Scholar
• Katlama C, Haubrich R, Lalezari J, Lazzarin A, Madruga JV, Molina JM, et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS. 2009;23(17):2289–2300.
   PubMed Web of Science ®Google Scholar
• Trottier B, Di Perri G, Madruga JV, Peeters M, Vingerhoets J, Picchio G, et al. Impact of the background regimen on virologic response to etravirine: pooled 48-week analysis of DUET-1 and -2. HIV Clin trials. 2010;11(4):175–185.
   PubMed Web of Science ®Google Scholar
• Scherrer AU, von Wyl V, Böni J, Yerly S, Klimkait T, Bürgisser P, et al. Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr. 2011;57(1):24–31.
   PubMed Web of Science ®Google Scholar
• Imaz A, Llibre JM, Ribera E, Clotet B, Podzamczer D. The role of inactive nucleoside/nucleotide reverse transcriptase inhibitors in salvage therapy for drug-resistant HIV-1 infection in the era of new classes and new generation antiretrovirals. J Acquir Immune Defic Syndr. 2011;58(2):46–48.
   Web of Science ®Google Scholar
• Katlama C, Assoumou L, Valantin MA, Soulié C, Duvivier C, Chablais L, et al. Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study. J Antimicrob Chemother. 2014;69(6):1648–1652.
   PubMed Web of Science ®Google Scholar